about
ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor CellsThe dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment.Developments in preclinical cancer imaging: innovating the discovery of therapeutics.Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment.Annexin A6 and Late Endosomal Cholesterol Modulate Integrin Recycling and Cell Migration.The Inositol Polyphosphate 5-Phosphatase PIPP Regulates AKT1-Dependent Breast Cancer Growth and Metastasis.The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking.Context-dependent intravital imaging of therapeutic response using intramolecular FRET biosensors.SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer.The cross-talk of LDL-cholesterol with cell motility: insights from the Niemann Pick Type C1 mutation and altered integrin trafficking.Intravital FRAP Imaging using an E-cadherin-GFP Mouse Reveals Disease- and Drug-Dependent Dynamic Regulation of Cell-Cell Junctions in Live Tissue.Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology.A RhoA-FRET Biosensor Mouse for Intravital Imaging in Normal Tissue Homeostasis and Disease Contexts.Cholesterol regulates Syntaxin 6 trafficking at trans-Golgi network endosomal boundaries.Evidence that TLR4 Is Not a Receptor for Saturated Fatty Acids but Mediates Lipid-Induced Inflammation by Reprogramming Macrophage Metabolism.MASTL overexpression promotes chromosome instability and metastasis in breast cancer.Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer.Removing physiological motion from intravital and clinical functional imaging dataCombating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicineCell matrix adhesion in cell migration
P50
Q27345430-17F138E7-2AED-4A6D-9AFE-4F173D1CD083Q36147572-2D6AD53B-F1D3-4581-A838-7EAEB101C42CQ38205100-C4B7BC87-D0DD-485F-8E96-42D974609ADAQ38218018-924A7CD5-24EE-4C93-93FC-533A15F8FF22Q38818776-8AD84DB4-A466-4195-A326-9B481395BD44Q38844189-98309D1C-5F2A-4DDD-B83A-E9D5161EEE9FQ38908701-1D26BC65-645D-42E1-97FC-2DD02B1B12D7Q39257470-73A1AD85-FB4F-4BD4-A7DF-733983E99C32Q41193853-A6F1CFE0-74A7-487F-A570-24F9FDD7EEAFQ41780762-A4DF1EE5-3656-440D-A53A-08B7645AB750Q42678959-6538D4FE-08CB-470E-BBF3-31F9EE05C085Q45987365-07315338-511B-4DD1-A3AA-3E15F596E16EQ47134459-65C7E3D0-9FC5-4B21-9932-00699DE68C78Q49600766-B7A2A706-1556-49A0-B1C6-F1C3554ABA32Q51749171-38DA9D88-5EA0-4B34-9293-450F3DB0300BQ52717686-9EB37A42-C15E-465A-9DB0-197EE4665E68Q54979446-8FE07A00-7365-4C69-A1D4-5A1CBD594779Q55400356-C8B9B707-A285-4E1A-97CC-63D334AB55FCQ56809927-DBBBFF2B-F86B-4A1B-A83D-88251B47ADF6Q58610296-DFD8403A-D449-45AF-8BC0-0017A291EEF1Q92831393-4FC7F379-E130-4564-B69C-6807BD50D43B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
James Rw Conway
@ast
James Rw Conway
@en
James Rw Conway
@es
James Rw Conway
@nl
type
label
James Rw Conway
@ast
James Rw Conway
@en
James Rw Conway
@es
James Rw Conway
@nl
prefLabel
James Rw Conway
@ast
James Rw Conway
@en
James Rw Conway
@es
James Rw Conway
@nl
P106
P31
P496
0000-0003-3787-277X